Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Curis Inc (CRIS)
NASDAQ:CRIS
Holding CRIS?
Track your performance easily
Earnings Data
Report Date
Mar 18, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$1.34Last Year’s EPS
-$2.03Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2024
|% Change Since: -18.95%
|Next Earnings Date:Mar 18, 2025
Earnings Call Sentiment|Positive
The earnings call highlights encouraging clinical trial results and effective cost management, as well as successful fundraising efforts. However, the ongoing net loss and enrollment challenges in the triplet study indicate areas of concern. Overall, the positive aspects of the clinical progress and financial management slightly outweigh the negatives.Company Guidance
During the Curis Third Quarter 2024 Earnings Call, the company provided guidance on its ongoing clinical trials and financial performance. Curis reported a net loss of $10.1 million or $1.70 per share for the third quarter of 2024, a decrease from the $12.2 million or $2.13 per share loss in the same period of 2023. The company highlighted its TakeAim Lymphoma study, which showed promising results with emavusertib and ibrutinib, reporting three complete responses and two partial responses among ten evaluable patients. The TakeAim Leukemia study also yielded positive results, with six of eleven evaluable patients achieving an objective response. Financially, research and development expenses decreased to $9.7 million, and general and administrative expenses reduced to $3.8 million, both compared to the same quarter of the previous year. Following a recent funding round, Curis's cash and cash equivalents stood at $31.6 million, expected to support operations into mid-2025. The company is actively engaging with regulatory authorities to define a path to approval for its treatments.Encouraging Results in TakeAim Lymphoma Study
The TakeAim Lymphoma study showed promising results with 10 evaluable patients, where there were 3 complete responses, 1 unconfirmed complete response, and 2 partial responses. The duration of response for 3 of the 4 patients with complete or unconfirmed complete responses was greater than 6 months.
Positive Progress in TakeAim Leukemia Study
In the TakeAim Leukemia study, 6 out of 11 evaluable patients with FLT3 mutation achieved an objective response, including 3 complete responses. Notably, 3 out of the 11 patients were naive to treatment with a FLT3 inhibitor, and all achieved an objective response.
Reduction in Net Loss and Expenses
Curis reported a net loss of $10.1 million for Q3 2024, a reduction from $12.2 million in Q3 2023. Research and development expenses decreased to $9.7 million from $10.4 million in the same period last year. General and administrative expenses also decreased to $3.8 million from $4.8 million.
Successful Fundraising
Curis completed a registered direct offering and private placement of unregistered warrants with net proceeds of approximately $10.8 million, bringing cash and cash equivalents to $31.6 million.
---
CRIS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CRIS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $3.93 | $3.98 | +1.27% |
| Aug 01, 2024 | $5.48 | $4.94 | -9.85% |
| May 07, 2024 | $16.17 | $16.20 | +0.19% |
| Feb 08, 2024 | $9.39 | $10.65 | +13.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Curis Inc (CRIS) report earnings?
Curis Inc (CRIS) is schdueled to report earning on Mar 18, 2025, TBA Not Confirmed.
What is Curis Inc (CRIS) earnings time?
Curis Inc (CRIS) earnings time is at Mar 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRIS EPS forecast?
CRIS EPS forecast for the fiscal quarter 2024 (Q4) is -$1.34.
---